Fierce BD&L Summit for Life Sciences 2023

Craig Farrell is a member of the Go-To-Market Strategy team at AlphaSense with responsibilities for both the Life Science vertical, as well as the enterprise search offering termed Internal Insights. He began his career in a Molecular Cytology research lab at Memorial Sloan Kettering... Read More →

Dr. Ravi Kiron based in California, USA is an experienced pharma/biotech executive with decades of experience in discovery R&D through late-stage clinical development, intellectual property and regulatory, technology & business development, M&A, strategy and product commercialization... Read More →

Dominic is currently a Senior Director, Search & Evaluation within AstraZeneca’s Oncology R&D Business Development group. Selected transactions that Dominic has completed include the licensing of TNB-486 (CD19/CD3 BiSpecific) from TeneoBio as well as the acquisition of Neogene Therapeutics... Read More →

Garrett Rhyasen is Vice President of Oncology Search & Evaluation at GSK, where he leads a team of BD professionals responsible for sourcing, technical evaluation, and business case delivery of partnering opportunities.Prior to GSK, Garrett was Executive Director of and Global Head... Read More →

Nikhil Mutyal, Ph.D. is Executive Director, Business Development and Licensing in Pacific Hub for Merck and Co (known as MSD outside of United States) based in San Francisco. Dr. Mutyal leads BD&L efforts for Oncology, Neuroscience and Cardiometabolic diseases for therapeutic opportunities... Read More →